放射性示踪剂市场基于(关键地区、市场参与者、规模和份额)- 到 2031 年的预测

  • Report Code : TIPRE00030001
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 150
Buy Now

【研究报告】放射性示踪剂市场预计将从2022年的146.7573亿美元增长到2030年的542.9657亿美元;预计从 2022 年到 2030 年,复合年增长率将达到 17.8%。

市场洞察和分析师观点:

慢性病患病率不断上升,核成像的使用不断增加技术推动放射性示踪剂市场的增长。放射性示踪剂诊断领域的研究和开发日益受到关注,预计也将推动放射性示踪剂市场的增长。放射性示踪剂是一种化合物,其中一个或多个原子被放射性同位素取代。放射性示踪剂可用于基于监测化学反应的放射性衰变来研究化学反应。它们还用于单光子发射计算机断层扫描 (SPECT)、正电子发射断层扫描 (PET) 和计算机放射性粒子追踪 (CARPT) 等技术中的流动可视化。

放射性示踪剂市场主要参与者专注于通过合作扩大地理覆盖范围并增强迎合庞大客户群的能力的战略举措。 2022年5月,Invicro在马萨诸塞州尼达姆开设了新的全球总部和实验室,以提供更多资源来支持制药和生物技术公司及其开发改变生活的药物。

增长动力和挑战:

人口老龄化加剧、社会行为改变、久坐生活方式增多以及城市化进程加快是导致肥胖和其他慢性病患病率上升的关键因素如糖尿病。此外,研究早已证实基因可导致慢性疾病,如心血管疾病 (CVD)、糖尿病、肥胖、阿尔茨海默病 (AD) 和抑郁症。

根据国家老龄化委员会的说法......,80% 65 岁及以上的成年人患有至少一种慢性病,而 68% 患有两种或两种以上。根据美国疾病控制与预防中心 (CDC) 的数据,到 2020 年,美国约有十分之六的人患有至少一种慢性病,十分之四的人患有两种或多种慢性病。

忙碌的生活方式引起的动脉粥样硬化、心绞痛、急性心肌梗死等心血管疾病已成为全球范围内死亡的重要原因。根据世界卫生组织提供的数据,心血管疾病是全世界死亡的主要原因,每年约有 1790 万人死亡。糖尿病是一种危及生命的慢性疾病,无法进行功能性治愈。所有类型的糖尿病都会导致身体不同部位出现各种并发症,并增加过早死亡的总体风险。心脏病、中风、肾衰竭、截肢、视力丧失和神经损伤是与糖尿病相关的主要并发症。据国际糖尿病联盟(IDF)称,北美糖尿病病例预计将从2017年的4600万增至2045年的6200万。该数据进一步报告称,2017年有4.25亿人患有糖尿病,这一数字预计将达到629人到 2045 年,全球将有 100 万人。在预测期内,该疾病的患病率可能会增加近 35%。因此,有效的检查是正确治疗慢性病的必要条件;因此,核物质被用于诊断和检查目的。这些核物质用于正电子发射断层扫描(PET)和单光子发射计算机断层扫描(SPECT)等诊断测试,以诊断神经系统疾病、心血管疾病、慢性肺病和慢性肾病等慢性疾病。多种放射性示踪剂的可用性使得根据疾病类型及其预后进行选择变得容易。因此,慢性病发病率的增加正在增加对放射性示踪剂的需求,积极有利于市场扩张。

战略洞察

放射性示踪剂市场细分和范围:

“全球放射性示踪剂市场”根据示踪剂类型、测试类型、应用、最终用户和地理位置进行细分。放射性示踪剂市场按示踪剂类型分为 Technetium-99m 和 Tc-97m、Iodine-131、Iron-59、Lutetium-171、铷 (Rb-82) 氯化物和氨 (N-13)、Scandium-46 , Seaborgium-269, Hassium-269, 柠檬酸镓 Ga 67, 前列腺特异性膜抗原 (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201、F-18 FDG、F-18 FAPI、Ga-68 FAPI、F-18 PSMA、DOTATOC/DOTANOC/DOTATATE (Ga-68) 等。根据测试类型,放射性示踪剂市场分为 PET、SPECT 等。按应用划分,放射性示踪剂市场分为肿瘤学、肺病学、神经病学、心脏病学等。就最终用户而言,放射性示踪剂市场分为医院和诊所、诊断中心、学术和研究机构等。从地理上看,放射性示踪剂市场分为北美(美国、加拿大和墨西哥)、欧洲(德国、法国、意大利、英国、俄罗斯和欧洲其他地区)、亚太地区(澳大利亚、中国、日本、印度、韩国和亚太其他地区)、中东和非洲(南非、沙特阿拉伯、阿联酋以及中东和非洲其他地区)以及南美洲和中美洲(巴西、阿根廷和其他地区)南美洲和中美洲)。

细分分析:

根据示踪剂类型,放射性示踪剂市场分为 Technetium-99m 和 Tc-97m、Iodine-131、Iron-59、Lutetium-171 、铷 (Rb-82) 氯化物和氨 (N-13)、Scandium-46、Seaborgium-269、Hassium-269、柠檬酸镓 Ga 67、前列腺特异性膜抗原 (PSMA) (Ga-68)、FDDNP (F -18) 和 FDOPA (F-18)、磷 32 和铬 51、铊 201、F-18 FDG、F-18 FAPI、Ga-68 FAPI、F-18 PSMA、DOTATOC/DOTANOC/DOTATATE(Ga -68),以及其他。其他细分市场在 2022 年占据最大市场份额,Seaborgium-269 和 PSMA GA68 预计 2022 年至 2030 年的复合年增长率最高为 28.4%。由于 F-18 FDG 是用于诊断癌症的最常见放射性示踪剂之一使用 PET 扫描技术对人体进行扫描,F-18 FDG 细分市场到 2022 年将占据第二大市场份额。 FDA 已批准 F-18 FDG PET 用于测量人脑中的区域葡萄糖代谢,以协助诊断癫痫发作。在稳态条件下,F-18 FDG 被细胞与其他糖竞争而摄取。一旦进入细胞,F-18 FDG 就会被己糖激酶磷酸化。这种磷酸化导致极性实体无法从细胞中扩散出来。该实体可以通过葡萄糖-6-磷酸酶去磷酸化为F-18 FDG,但去磷酸化发生缓慢。因此,F-18 FDG的细胞浓度密切代表F-18 FDG的积累和外源葡萄糖的糖酵解活性。根据特定时期内组织中积累的量,可以计算该组织的葡萄糖摄取率。糖酵解加速和有氧产生能量的能力下降是恶性和致癫痫脑细胞的特征。这些特征导致维持细胞所需的高葡萄糖摄取率。上述因素推动了该领域放射性示踪剂市场的增长。

放射性示踪剂市场,按来源 - 2020 年和 2028 年

区域分析:

根据地理位置,放射性示踪剂市场分为五个关键地区:北美、欧洲、亚太地区、南美洲和中美洲、中东和非洲。 2020年,北美在全球放射性示踪剂市场中占据最大份额,预计亚太地区2022年至2030年的复合年增长率最高。

北美是放射性示踪剂最大的市场,美国占有最大的市场份额,其次是加拿大。美国放射性示踪剂市场的主要驱动因素是癌症诊断中对 PET 扫描仪的需求不断增长、对 SPECT 和 PET 等成像方式的需求不断增长以及放射性示踪剂的高采用率。过去几年,癌症诊断中对 SPECT 和 PET 扫描仪的需求显着增加。 SPECT 和 PET 提供了先进的诊断工具,可以检测每个阶段的疾病进展,有助于疾病的早期诊断。免疫 PET 是一种使用放射性示踪剂瞄准特定癌细胞的技术。该技术有助于可视化免疫治疗药物在肿瘤中的分布和积累,从而实现个性化治疗计划。因此,由于其广泛的益处,美国对放射性示踪剂的需求很大。

由于技术的进步,例如混合成像、用于诊断和治疗的新型放射性药物的引入,以及基于示踪剂原理的分子成像的发展。

一些市场参与者正在采取有机策略来保持市场竞争力。例如,2023年3月,Telix Pharmaceuticals 获得 FDA 批准 Illuccix 的补充新药申请 (sNDA),Illuccix 是一种旨在制备镓 Ga 68 gozetotide 注射液的试剂盒。该批准使 Illuccix 能够选择可从 177Lu 177 PSMA 定向治疗中受益的转移性前列腺癌患者。

行业发展和未来机遇:

欧盟委员会已采取采取各种举措来促进放射性示踪剂和放射性同位素的研发活动。美国能源部同位素计划 (DOE IP) 及其前身组织一直引领全球放射性同位素和稳定同位素的开发和生产。根据 1954 年《原子能法案》,能源部 IP 向美国提供同位素及相关服务,并在能源部内拥有生产用于分销和销售的同位素的独家权力。 DOE IP 的使命是进行研发,以开发变革性的同位素生产、分离和浓缩技术,以实现学术、联邦和工业创新、研究和新兴技术。

同位素生产美国能源部核能办公室设立了能源部核能和分配计划(IPDP),以加强能源部生产的同位素的生产和销售,用于研究和商业目的。 IPDP 的成立条件是其运作必须在财务上自给自足。

PRISMAP 是欧洲医用放射性核素计划,旨在为医学研究提供高纯度新型放射性同位素。根据该计划提供的数据,在欧盟实验室科学家合成的约 3,000 种不同放射性同位素中,只有少数经常用于医疗程序,主要用于成像。许多医院和研究机构致力于开发和使用不同的放射性示踪剂来诊断慢性疾病。马萨诸塞州总医院 (MGH) 致力于使用新型 PET 示踪剂 [18F]3F4AP 来诊断多发性硬化症、阿尔茨海默病、轻度认知障碍和创伤性脑损伤。根据国家医学图书馆 (ClinicalTrials.gov) 的资料,[18F]3F4AP 在 1 期临床试验中用于诊断多发性硬化症、阿尔茨海默病、轻度认知障碍和创伤性脑损伤。正在进行的寻找用于诊断神经系统疾病的新型放射性示踪剂的研究预计将在未来几年推动放射性示踪剂市场的增长。

COVID-19 影响:

COVID-19 大流行深刻地改变了医院活动,包括全球范围内的核医学 (N)M 实践。对 PubMed 进行了文献检索,涵盖了截至 2021 年 1 月发表的 COVID-19 研究。研究结果显示,这一流行病给 NM 部门带来了巨大挑战,欧洲每个中心都经历了劳动力减少。新墨西哥州各部门采取了限制措施来限制 COVID-19 的传播,包括重新安排非高优先级程序。此外,受疫情影响,一些部门的放射性药物或技术援助的供应出现延误。结果,大流行导致诊断和治疗 NM 程序显着减少,并降低了对受 COVID-19 以外疾病影响的患者的护理水平。根据英国核医学会 (BNMS) COVID-19 调查结果,约 97% 的 NM 部门采取了限制 SARS-CoV-2 传播的程序; 68%的工厂制定了标准化操作程序,用于在大流行情况下运行部门。疫情影响了 NM 大部分部门的工作流程。根据 Freudenberg 等人的全球调查,近 15% 的受访部门调整了不到 20% 员工的工作时间,诊断程序平均减少了 54.4%。 PET/CT 扫描平均减少 36%;甲状腺扫描减少 67%;心肌研究增加了 66%;骨扫描减少 60%;肺部扫描减少 56%;前哨淋巴结手术减少了 45%。来自德国、奥地利和瑞士的几乎所有 (97%) 参与调查的中心均报告诊断性 NM 程序有所下降。此外,核心脏病学是该地区 COVID-19 大流行期间 NM 受影响最严重的分支之一。所有非紧急检查均被推迟,2020 年 4 月和 5 月,NHS 英格兰 PET/CT 服务的活动量分别减少了 32% 和 31%。然而,欧洲中心的放射性同位素、发电机和套件的供应并未出现严重中断。 BNMS 调查报告称,81% 的参与者没有遇到任何放射性药物供应问题,13.9% 的参与者偶尔会出现问题,5.1% 的参与者经历过供应中断。

除此之外,支持 COVID-19 的新发现诊断预计将加速该地区放射性药物的增长。例如,根据 Chentao Jin 等人于 2021 年 5 月发表在《欧洲核医学和分子影像杂志》上的研究,PET 有望提供 COVID-19 的病理生理学变化,并促进患者的临床管理。鉴于 PET 在 COVID-19 大流行期间的作用,这些研究还可以为未来对抗其他流行病铺平道路。

竞争格局和主要公司:

全球放射性示踪剂市场的一些知名参与者包括 Rotem Industries Ltd、ABX Advanced Biochemicalcompound GmbH、Invicro LLC、Cardinal Health Inc、纽卡斯尔大学、诺华公司、Curium、Blue Earth Diagnostics Limited、通用电气公司和 IBA Radiopharma Solutions。这些公司专注于新产品发布和地域扩张,以满足全球不断增长的消费者需求,并增加其专业产品组合的产品范围。他们在全球拥有广泛的影响力,能够为大量客户提供服务,从而提高市场份额。
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What are the driving factors for the radioactive tracer market across the globe?

Factors such as rising prevalence of chronic diseases and increased use of nuclear imaging techniques are the key driving the growth of the radioactive tracer market.

Who are the key players in the radioactive tracer market?

Answer: - Rotem Industries Ltd, Abx Advanced Biochemical Compounds Gmbh, Invicro Llc; Cardinal Health Inc; Newcastle University, Novartis Ag; Curium, Blue Earth Diagnostics Limited, General Electric Co, Iba Radiopharma Solutions among others are among the leading companies operating in the radioactive tracer market.

Which segment led the radioactive tracer market?

Based on tracer type, the others segment held the largest market share in 2022, and Seaborgium-269 and PSMA GA68 is anticipated to register the highest CAGR of 28.4% during the forecast period.

Which end user segment held the largest revenue (US$ Mn) in the radioactive tracer market?

The hospitals & clinics segment held the largest share of the market in 2022 and academic & research institutes is anticipated to register the highest CAGR of 20.6% in the market during the forecast period.

What is meant by the radioactive tracer market?

A radioactive tracer is a chemical compound in which one or more atoms have been replaced by a radioisotope. Through monitoring its radioactive decay, a radiotracer can be used to study chemical reactions. Through different technologies, they are also used to visualize flow, including Single Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and Computed Radioactive Particle Tracking (CARPT).

The List of Companies - Radioactive Tracer Market

  1. Rotem Industries Ltd
  2. Abx Advanced Biochemical Compounds Gmbh
  3. Invicro Llc
  4. Cardinal Health Inc
  5. Newcastle University
  6. Novartis AG
  7. Curium
  8. Blue Earth Diagnostics Limited
  9. General Electric Co
  10. IBA Radiopharma Solutions

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports